ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study now provides a full list of patient cohort expansions and closures on its website. Based on treatment responses in Stage I, patient cohorts are either expanded to Stage II for further study and identification of a signal or permanently closed. ASCO’s TAPUR Study offers a clinical trial opportunity for patients with advanced cancer who have not responded or are no longer responding to standard treatment and who have genomic alterations in their tumors that can be targeted with a TAPUR Study drug.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.